Skip to main content
. 2023 Jun 19;13(6):e1300. doi: 10.1002/ctm2.1300

FIGURE 5.

FIGURE 5

DUXAP8 is a key contributor to sorafenib resistance. To explore the role of DUXAP8 in sorafenib resistance of HCC cells, the HCC sorafenib‐resistant cell line SMMC‐7721‐SR (IC50 14.78 μg/mL) and sorafenib‐sensitive parental cell line SMMC‐7721‐WT (IC50 2.46 μg/mL) were used for in vitro tests. (A) Comparison of sorafenib resistance between SR and WT cells (CCK8 assay). (B) Comparison of DUXAP8 expression between SR and WT cells (qRT‐PCR assay). The statistical chart represents the comparison of cell growth inhibition rates of WT and SR cells after knockdown of DXUXAP8. (C) Inhibitory effect of DUXAP8 knockdown on the cell viability of both sorafenib‐treated wide‐type and sorafenib‐resistant cells measured by using the RTCA system. (D, E) DUXAP8 knockdown remarkably enhanced the changes of the MDA concentration (D) and GSSG/GSH ratio (E) induced by sorafenib (5 μM) in SMMC‐7721‐SR cells. (F) DUXAP8 knockdown enhanced the sorafenib (5 μM)—induced increases of ROS (red), ferrous iron (yellow), and intracellular lipid ROS (green) in sorafenib‐resistant cells. Magnification: ×200. * p < 0.05, ** p < 0.01, *** p < 0.001. Results represent three independent experiments. WT, SMMC‐7721‐WT; SR, SMMC‐7721‐SR; sh‐DUX, sh‐DUXAP8.